MX2020006305A - Vacunas de cancer dirigidas a lemd1 y sus usos. - Google Patents

Vacunas de cancer dirigidas a lemd1 y sus usos.

Info

Publication number
MX2020006305A
MX2020006305A MX2020006305A MX2020006305A MX2020006305A MX 2020006305 A MX2020006305 A MX 2020006305A MX 2020006305 A MX2020006305 A MX 2020006305A MX 2020006305 A MX2020006305 A MX 2020006305A MX 2020006305 A MX2020006305 A MX 2020006305A
Authority
MX
Mexico
Prior art keywords
lemdl
lemd1
disclosed
cancer vaccines
vaccines targeting
Prior art date
Application number
MX2020006305A
Other languages
English (en)
Inventor
Jian Yan
Neil Cooch
Anna Slager
Bradley Garman
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of MX2020006305A publication Critical patent/MX2020006305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se describen moléculas de ácido nucleico que comprenden una o más secuencias de ácido nucleico que codifican un antígeno de LEMD1 de consenso mutada. Se describen vectores, composiciones y vacunas que comprenden una o más secuencias de ácido nucleico que codifican un antígeno de LEMD1 de consenso mutada. Se describen métodos para tratar a un sujeto con un tumor que expresa LEMD1 y métodos para prevenir un tumor que expresa LEMD1. Se revela el antígeno de LEMD1 de consenso mutada.
MX2020006305A 2017-12-13 2018-12-13 Vacunas de cancer dirigidas a lemd1 y sus usos. MX2020006305A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598329P 2017-12-13 2017-12-13
US201762598612P 2017-12-14 2017-12-14
PCT/US2018/065534 WO2019118771A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof

Publications (1)

Publication Number Publication Date
MX2020006305A true MX2020006305A (es) 2020-09-17

Family

ID=66734873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006305A MX2020006305A (es) 2017-12-13 2018-12-13 Vacunas de cancer dirigidas a lemd1 y sus usos.

Country Status (11)

Country Link
US (2) US11338028B2 (es)
EP (1) EP3724217A4 (es)
JP (2) JP7314139B2 (es)
KR (1) KR20200096959A (es)
CN (1) CN111479822A (es)
AU (2) AU2018384824B2 (es)
BR (1) BR112020011620A2 (es)
CA (1) CA3084137A1 (es)
MX (1) MX2020006305A (es)
RU (1) RU2760984C1 (es)
WO (1) WO2019118771A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ573831A (en) * 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
CN100478689C (zh) * 2002-08-30 2009-04-15 肿瘤疗法科学股份有限公司 多肽及其用途
EP1954826A4 (en) 2005-11-27 2010-05-05 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND TESTS AND METHOD FOR THEIR USE FOR DIAGNOSIS
CN102850434B (zh) 2006-10-17 2016-04-13 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
KR101174452B1 (ko) * 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
PL391627A1 (pl) 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN103890587A (zh) * 2011-08-31 2014-06-25 昂科赛特公司 用于治疗和诊断癌症的方法和组合物
US20140315743A1 (en) * 2011-10-03 2014-10-23 Karen Chapman Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10220082B2 (en) 2012-12-13 2019-03-05 Inovio Pharmaceuticals, Inc. WT1 vaccine
US20190292601A1 (en) * 2016-05-23 2019-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens

Also Published As

Publication number Publication date
US11338028B2 (en) 2022-05-24
CN111479822A (zh) 2020-07-31
CA3084137A1 (en) 2019-06-20
JP2021506264A (ja) 2021-02-22
AU2018384824A8 (en) 2020-07-30
EP3724217A4 (en) 2022-01-12
JP7314139B2 (ja) 2023-07-25
US20190175712A1 (en) 2019-06-13
RU2760984C1 (ru) 2021-12-02
AU2018384824B2 (en) 2022-08-04
BR112020011620A2 (pt) 2020-12-08
JP2023111915A (ja) 2023-08-10
US20220265800A1 (en) 2022-08-25
AU2018384824A1 (en) 2020-07-16
AU2022263546A1 (en) 2022-12-08
WO2019118771A1 (en) 2019-06-20
EP3724217A1 (en) 2020-10-21
KR20200096959A (ko) 2020-08-14

Similar Documents

Publication Publication Date Title
PH12019502518A1 (en) Alphavirus neoantigen vectors
PH12019501959A1 (en) Therapeutic rna
PH12018500964A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
MX364732B (es) Vacuna contra el tumor de wilms 1.
MX2022001085A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
EP4197551A3 (en) Adoptive cell transfer and oncolytic virus combination therapy
MX2018008051A (es) Variantes de beta-glucanasa y polinucleotidos que las codifican.
EP3998341A3 (en) Adenoviral vectors
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2018005872A (es) Profarmacos de acido nucleico.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201990370A1 (ru) Терапия рака, связанная с crebbp
MX2020006216A (es) Vacunas contra el cancer dirigidas a prame y sus usos.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
MX2020006305A (es) Vacunas de cancer dirigidas a lemd1 y sus usos.